TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

INFASURF PRESERVATIVE FREE

CALFACTANT Surfactant Activity
Respiratory Approved 1998-07-01
1
Indication
--
Phase 3 Trials
27
Years on Market

Details

Status
Prescription
First Approved
1998-07-01
Routes
INTRATRACHEAL
Dosage Forms
SUSPENSION

Companies

Active Ingredient: CALFACTANT

INFASURF PRESERVATIVE FREE Approval History

Loading approval history...

What INFASURF PRESERVATIVE FREE Treats

1 indications

INFASURF PRESERVATIVE FREE is approved for 1 conditions since its original approval in 1998. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Respiratory Distress Syndrome
Source: FDA Label

Drugs Similar to INFASURF PRESERVATIVE FREE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

INFASURF PRESERVATIVE FREE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. INFASURF ® is a surfactant indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates < 29 weeks gestational age at risk for RDS. for the rescue treatment of preterm neonates ≤72 hours of age with RDS who require endotracheal intubation.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.